Trial Profile
A Study to Evaluate the Effectiveness and Safety of Rivaroxaban Versus Warfarin or Dabigatran Etexilate in Patients With Non-Valvular Atrial Fibrillation Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2016
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Stroke; Thrombosis
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2016 New trial record
- 27 May 2016 Results published in the Pharmacoepidemiology and Drug Safety